Cisplatin based therapy: the role of the mitogen activated protein kinase signaling pathway
Open Access
- 11 April 2018
- journal article
- review article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 16 (1) , 1-12
Abstract
Cisplatin is a widely used chemotherapeutic agent for treatment of various cancers. However, treatment with cisplatin is associated with drug resistance and several adverse side effects such as nephrotoxicity, reduced immunity towards infections and hearing loss. A Combination of cisplatin with other drugs is an approach to overcome drug resistance and reduce toxicity. The combination therapy also results in increased sensitivity of cisplatin towards cancer cells. The mitogen activated protein kinase (MAPK) pathway in the cell, consisting of extracellular signal regulated kinase, c-Jun N-terminal kinase, p38 kinases, and downstream mediator p90 ribosomal s6 kinase (RSK); is responsible for the regulation of various cellular events including cell survival, cell proliferation, cell cycle progression, cell migration and protein translation. This review article demonstrates the role of MAPK pathway in cisplatin based therapy, illustrates different combination therapy involving cisplatin and also shows the importance of targeting MAPK family, particularly RSK, to achieve increased anticancer effect and overcome drug resistance when combined with cisplatin.Keywords
Funding Information
- Qatar University Internal Grant (QUUG-CPH\ 2017-4)
This publication has 104 references indexed in Scilit:
- Anvirzel™ in combination with cisplatin in breast, colon, lung, prostate, melanoma and pancreatic cancer cell linesBMC Pharmacology and Toxicology, 2013
- p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cellsJournal of Clinical Investigation, 2010
- RSK in tumorigenesis: Connections to steroid signalingSteroids, 2010
- The RSK family of kinases: emerging roles in cellular signallingNature Reviews Molecular Cell Biology, 2008
- Codependent Functions of RSK2 and the Apoptosis-Promoting Factor TIA-1 in Stress Granule Assembly and Cell SurvivalMolecular Cell, 2008
- Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignanciesMolecular Cancer Therapeutics, 2008
- FGFR3 Activates RSK2 to Mediate Hematopoietic Transformation through Tyrosine Phosphorylation of RSK2 and Activation of the MEK/ERK PathwayCancer Cell, 2007
- Regulation of p73-mediated apoptosis by c-Jun N-terminal kinaseBiochemical Journal, 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Apoptosis: A Review of Programmed Cell DeathToxicologic Pathology, 2007